PDC Therapeutics Announces Poster Presentation at the ESMO TAT 2023 Congress

15 March 2023

PDC Therapeutics, a nanomedicines biotech company developing targeted Polymer Drug Conjugates that are aiming to provide cancer patients with an optimal therapeutic index, announced the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as “The Home of Phase I in Oncology”.

PDC Therapeutics’ platform technology allows designing targeted drug candidates for different indications, which yields into development of the company’s own portfolio, as well as an important co-development potential. The nanocarriers introduce a versatile targeting capability and are suitable for loading a single or a combination of chemotherapeutic agents, with superior pharmacokinetic profiles while the targeting enables the drugs to accumulate in the tumor ensuring an enhanced therapeutic index and thus offering reduced toxicity profile.

RS-0139 is the lead candidate in Phase I clinical trial, aiming to deliver docetaxel specifically into integrin receptor expressing tumors such as NSCLC, breast, ovarian, prostate and pancreatic as well as head & neck carcinoma. PDC Therapeutics Medical Director Gülşah Nomak, MD presented the candidates’ promising preclinical data at ESMO TAT 2023.

Poster Title:      RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

Date:                   6 March 2023

Location:             Hall Bordeaux

Poster No:           100P

Presenter:           Prof. Rana Sanyal, PhD; Gülşah Nomak, MD

The poster abstract is available online at the ESMO TAT 2023 website.

⤓ Poster

PDC Therapeutics

PDC Therapeutics is a nanomedicines biotech company, developing targeted Polymer Drug Conjugates that are aiming to provide cancer patients with an optimal therapeutic index for a “Cure with A Smile”. Our nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development. Cooperating with multinational pharmaceutical companies through co-development programs, PDC therapeutics is supported by an industry experienced board of scientific and supervisory experts around the world. PDC Therapeutics is scientifically backed by RS Research, an academic spin-off which has developed a pioneering class of nanocarriers with targeting capability of different indications.

For detailed information:

For media inquiries: pr@pdcbio.com
For technical inquiries: medicalinformation@pdcbio.com